Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.

INTRODUCTION:Chemotherapy-related endothelial damage contributes to the early development of cardiovascular morbidity in testicular cancer patients. We aimed to identify relevant mechanisms of and search for candidate biomarkers for this endothelial damage. METHODS:Human micro-vascular endothelial c...

Full description

Bibliographic Details
Main Authors: Renske Altena, Rudolf S N Fehrmann, Hink Boer, Elisabeth G E de Vries, Coby Meijer, Jourik A Gietema
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4295859?pdf=render
id doaj-c2e0dd6f6ca04d7599dca48731444fee
record_format Article
spelling doaj-c2e0dd6f6ca04d7599dca48731444fee2020-11-24T22:00:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01101e011537210.1371/journal.pone.0115372Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.Renske AltenaRudolf S N FehrmannHink BoerElisabeth G E de VriesCoby MeijerJourik A GietemaINTRODUCTION:Chemotherapy-related endothelial damage contributes to the early development of cardiovascular morbidity in testicular cancer patients. We aimed to identify relevant mechanisms of and search for candidate biomarkers for this endothelial damage. METHODS:Human micro-vascular endothelial cells (HMEC-1) were exposed to bleomycin or cisplatin with untreated samples as control. 18k cDNA microarrays were used. Gene expression differences were analysed at single gene level and in gene sets clustered in biological pathways and validated by qRT-PCR. Protein levels of a candidate biomarker were measured in testicular cancer patient plasma before, during and after bleomycin-etoposide-cisplatin chemotherapy, and related to endothelial damage biomarkers (von Willebrand Factor (vWF), high-sensitivity C-Reactive Protein (hsCRP)). RESULTS:Microarray data identified several genes with highly differential expression; e.g. Growth Differentiation Factor 15 (GDF-15), Activating Transcription Factor 3 (ATF3) and Amphiregulin (AREG). Pathway analysis revealed strong associations with 'p53' and 'Diabetes Mellitus' gene sets. Based on known function, we measured GDF-15 protein levels in 41 testicular patients during clinical follow-up. Pre-chemotherapy GDF-15 levels equalled controls. Throughout chemotherapy GDF-15, vWF and hsCRP levels increased, and were correlated at different time-points. CONCLUSION:An unbiased approach in a preclinical model revealed genes related to chemotherapy-induced endothelial damage, like GDF-15. The increases in plasma GDF-15 levels in testicular cancer patients during chemotherapy and its association with vWF and hsCRP suggest that GDF-15 is a potentially useful biomarker related to endothelial damage.http://europepmc.org/articles/PMC4295859?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Renske Altena
Rudolf S N Fehrmann
Hink Boer
Elisabeth G E de Vries
Coby Meijer
Jourik A Gietema
spellingShingle Renske Altena
Rudolf S N Fehrmann
Hink Boer
Elisabeth G E de Vries
Coby Meijer
Jourik A Gietema
Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.
PLoS ONE
author_facet Renske Altena
Rudolf S N Fehrmann
Hink Boer
Elisabeth G E de Vries
Coby Meijer
Jourik A Gietema
author_sort Renske Altena
title Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.
title_short Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.
title_full Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.
title_fullStr Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.
title_full_unstemmed Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.
title_sort growth differentiation factor 15 (gdf-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description INTRODUCTION:Chemotherapy-related endothelial damage contributes to the early development of cardiovascular morbidity in testicular cancer patients. We aimed to identify relevant mechanisms of and search for candidate biomarkers for this endothelial damage. METHODS:Human micro-vascular endothelial cells (HMEC-1) were exposed to bleomycin or cisplatin with untreated samples as control. 18k cDNA microarrays were used. Gene expression differences were analysed at single gene level and in gene sets clustered in biological pathways and validated by qRT-PCR. Protein levels of a candidate biomarker were measured in testicular cancer patient plasma before, during and after bleomycin-etoposide-cisplatin chemotherapy, and related to endothelial damage biomarkers (von Willebrand Factor (vWF), high-sensitivity C-Reactive Protein (hsCRP)). RESULTS:Microarray data identified several genes with highly differential expression; e.g. Growth Differentiation Factor 15 (GDF-15), Activating Transcription Factor 3 (ATF3) and Amphiregulin (AREG). Pathway analysis revealed strong associations with 'p53' and 'Diabetes Mellitus' gene sets. Based on known function, we measured GDF-15 protein levels in 41 testicular patients during clinical follow-up. Pre-chemotherapy GDF-15 levels equalled controls. Throughout chemotherapy GDF-15, vWF and hsCRP levels increased, and were correlated at different time-points. CONCLUSION:An unbiased approach in a preclinical model revealed genes related to chemotherapy-induced endothelial damage, like GDF-15. The increases in plasma GDF-15 levels in testicular cancer patients during chemotherapy and its association with vWF and hsCRP suggest that GDF-15 is a potentially useful biomarker related to endothelial damage.
url http://europepmc.org/articles/PMC4295859?pdf=render
work_keys_str_mv AT renskealtena growthdifferentiationfactor15gdf15plasmalevelsincreaseduringbleomycinandcisplatinbasedtreatmentoftesticularcancerpatientsandrelatetoendothelialdamage
AT rudolfsnfehrmann growthdifferentiationfactor15gdf15plasmalevelsincreaseduringbleomycinandcisplatinbasedtreatmentoftesticularcancerpatientsandrelatetoendothelialdamage
AT hinkboer growthdifferentiationfactor15gdf15plasmalevelsincreaseduringbleomycinandcisplatinbasedtreatmentoftesticularcancerpatientsandrelatetoendothelialdamage
AT elisabethgedevries growthdifferentiationfactor15gdf15plasmalevelsincreaseduringbleomycinandcisplatinbasedtreatmentoftesticularcancerpatientsandrelatetoendothelialdamage
AT cobymeijer growthdifferentiationfactor15gdf15plasmalevelsincreaseduringbleomycinandcisplatinbasedtreatmentoftesticularcancerpatientsandrelatetoendothelialdamage
AT jourikagietema growthdifferentiationfactor15gdf15plasmalevelsincreaseduringbleomycinandcisplatinbasedtreatmentoftesticularcancerpatientsandrelatetoendothelialdamage
_version_ 1725845307978153984